Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of New Cumulative Doses of Grass MATA MPL in Seasonal Allergic Rhinoconjunctivitis
NCT02557633Phase 1Completed
- Sponsor
- Allergy Therapeutics PLC
- Start
- Aug 2015
- Primary completion
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Grass MATA MPL in Seasonal Allergic Rhinoconjunctivitis (SAR) (3 arms), sponsored by Allergy Therapeutics PLC. Primary endpoints: Number of Adverse Events at 8 weeks and Premature Discontinuation at 8 weeks. Started Aug 2015; status: completed.
02
Drugs
Grass MATA MPL
03
Conditions
Seasonal Allergic Rhinoconjunctivitis (SAR)
Beyond the preview
Go deeper on NCT02557633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557633.